Dr. PingLi


Munich +

Dr. Ping Li focuses her practice on biotechnological, pharmaceutical, and chemical patents involving nanoparticle and macromolecule drugs, small molecule antiviral and anticancer therapies, polymer technology, chemical engineering, and lithium-ion battery technology. In addition to patent drafting, prosecution, opposition, and appeal proceedings, Ping has particular experience in matters relating to supplementary protection certificates (SPCs) including assisting and advising clients on obtaining SPCs and creating SPC portfolios in Europe. She also has experience in IP due diligence, freedom-to-operate analysis, and patent validity opinion and has been involved in German as well as cross-border patent infringement and revocation proceedings. Ping joined Jones Day in May 2008.

Ping is a chemist and a structural biologist by training with technical experience in organic and inorganic synthesis, NMR (nuclear magnetic resonance) spectroscopy, molecular biology, protein crystallography, protein expression and purification, RNA (ribonucleic acid) biochemistry, virology, antibody, chromatography, mass spectroscopy, electron microscopy, and radioactive labeling. Her doctoral work at the Max Planck Institute for Biophysical Chemistry led to several peer-reviewed publications including a first author publication in the journal Science in 2007. Ping's scientific background allows her to quickly grasp the essence of inventions relating to a broad spectrum of technological fields.

Ping is a member of the Institute of Professional Representatives before the European Patent Office (epi), the German Patent Bar Association, the International Federation of Intellectual Property Attorneys, and the German Association for the Protection of Intellectual Property (GRUR).


  • Sunovion establishes global patent portfolio for small molecule drugs for certain CNS disorders and painJones Day assists Sunovion Pharmaceuticals Inc. in the establishment of a global patent portfolio related to small molecule drugs for the treatment of certain CNS disorders and pain.
  • Idenix establishes patent portfolio related to nucleoside analog antiviral drugsJones Day represents Idenix Pharmaceuticals, Inc. in the management and development of a patent portfolio related to nucleoside analog antiviral drugs.
  • Leading manufacturer of low ignition proclivity papers engages in European oppositionsJones Day represents a leading paper manufacturer before the European Patent Office. 
  • Stopaq asserts in Germany several patents against competitor involving self-healing, anti-corrosion preparations for use on oil and gas pipelinesJones Day is advising Stopaq B.V., a Netherlands-based manufacturer of corrosion protective coatings and sealants, in a multi-patent litigation against a major competitor.
    • December 13, 2021
      Women in IP Speaker Series: Artificial Intelligence in the Biopharma Lifecycle: U.S. and EU IP Considerations
    • June 6, 2019
      Successful claim strategies for inventions arising from product development and emerging technologies: US v. EP, AbbVie IP Day 2019
    • September 16, 2015
      Opposition Proceedings at the EPO Webinar